09:53 AM EST - Stem Cell Therapeutics Corp. : announced that it has filed articles of amalgamation to merge with its wholly-owned subsidiary Trillium Therapeutics Inc. The combined company has adopted the Trillium name. Stem Cell Therapeutics Corp.
shares T.SSS are trading unchanged at $0.29.
